Get to know our clinical trials
Clinical trial of bleximenib, venetoclax and azacitidine for the treatment of newly diagnosed acute myeloid leukemia patients with KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy
THE AIM OF THIS STUDY IS TO HELP RESEARCHERS BETTER UNDERSTAND THE POTENTIAL EFFICACY AND SAFETY OF BLEXIMENIB (ALSO KNOWN AS JNJ-75276617) IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML) WITH KMT2A OR NPM1 DNA ABNORMALITIES WHEN ADMINISTERED IN ADDITION TO REFERENCE DRUGS, VENETOCLAX AND AZACITIDINE.
Technical Summary
- Code EudraCT: 2024-520154-38
- Protocol number: 75276617AML3001
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.